Key Takeaways
- Danish pharmaceutical giant Novo Nordisk has entered a licensing agreement worth up to $2.6 billion with China’s Jiangsu Hengrui Pharmaceuticals for an experimental weight-loss pill.
- The agreement features a $300 million initial payment alongside potential milestone-based payments totaling $2.3 billion.
- HRS-1596, the licensed compound, functions as a dual GLP-1/GIP receptor agonist designed for weekly administration.
- Shares of Novo have plummeted over 70% from peak levels amid intensifying competition from Eli Lilly in the obesity treatment sector.
- Hengrui’s Hong Kong-traded shares climbed approximately 2% following the deal announcement.
The Danish pharmaceutical manufacturer has watched its market value decline by more than 70% from all-time highs as rival Eli Lilly captures increasing market share in the lucrative obesity therapeutics space. The company announced its latest strategic countermove on Tuesday.
Novo Nordisk announced a licensing arrangement valued at up to $2.6 billion to secure rights to an investigational obesity treatment from Jiangsu Hengrui Pharmaceuticals based in China. This represents the company’s second GLP-1 partnership with a Chinese firm in 2025.
Under the terms, Novo obtains worldwide commercialization rights to HRS-1596, excluding mainland China, Hong Kong, Macao, and Taiwan. Hengrui retains exclusive rights within those territories.
The compound HRS-1596 targets both GLP-1 and GIP receptors and remains in early-stage clinical development. Chinese regulatory authorities have greenlit Phase 1 studies evaluating the drug for obesity management and type 2 diabetes treatment.
Financial Structure of the Agreement
The Chinese pharmaceutical company will receive an immediate payment of $300 million from Novo. The remaining $2.3 billion comprises contingent payments tied to development achievements, regulatory approvals, and commercial performance, supplemented by ongoing royalty payments.
Novo indicated the oral medication could ultimately require dosing just once weekly. This represents a significant advancement over existing daily pill formulations, including Wegovy.
Chief Executive Mike Doustdar stated earlier in April that oral medications would assume greater importance in obesity treatment strategies moving forward. This licensing agreement aligns directly with that strategic vision.
A company representative informed Reuters that Novo intends to launch international clinical trials for HRS-1596. Specific timelines remain undisclosed at this stage.
Intensifying Market Rivalry and Chinese Innovation
The company faces fierce competition from Eli Lilly, whose oral medication Foundayo directly challenges Wegovy in the marketplace. This competitive pressure has contributed to sustained weakness in Novo’s share price.
China has emerged as a powerhouse for obesity drug development. According to Pharmcube analytics, nearly 250 GLP-1 drug candidates originating from Chinese companies are currently under investigation.
Major global pharmaceutical corporations have pursued comparable strategies. AstraZeneca, Merck, and Pfizer have each secured licensing agreements for GLP-1 compounds from Chinese biotechnology firms.
Novo previously established a partnership with United Laboratories International, another Chinese entity, for the compound UBT251. Clinical data showed participants achieving weight reduction of up to 19.7% over a 24-week treatment period.
Industry analysts project the global obesity pharmaceutical market will reach approximately $100 billion in annual revenues within ten years. This substantial opportunity explains the surge in licensing transactions across the sector.
Hengrui’s Hong Kong-listed shares gained roughly 2% following the partnership disclosure. This uptick contrasted with the broader Hang Seng Index, which declined about 1% during the same trading session.
The transaction remains subject to clearance from U.S. antitrust regulators and other customary closing requirements. Both Novo and Hengrui anticipate finalizing the agreement during the fourth quarter of 2026.
Eli Lilly declined to comment when asked whether the company has pursued similar licensing arrangements with Chinese pharmaceutical developers.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
